Auxly Cannabis Group Inc
Auxly Cannabis Group Inc is a Canadian company that operates in the pharmaceuticals and medical research sector, focusing on cannabis-based products and therapies.
Business. Auxly Cannabis Group Inc (XLY.TO) is a healthcare company operating within the pharmaceuticals and medical research industry. The firm is headquartered in Canada and is primarily listed on the Toronto Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Auxly Cannabis Group Inc (XLY.TO) is a healthcare company operating within the pharmaceuticals and medical research industry. The firm is headquartered in Canada and is primarily listed on the Toronto Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Auxly Cannabis Group Inc has a liquidity position that is below the industry median, with a current ratio of 0.71, indicating that the company's current assets are insufficient to cover its current liabilities. The company's cash and equivalents amount to 13,079,000 CAD, while its long-term debt stands at 81,727,000 CAD, resulting in a debt-to-equity ratio of 0.79. This suggests that the company is moderately leveraged but not in a high-risk debt position.
The company's profitability is weak, with a net loss of 26,012,000 CAD and an operating loss of 9,829,000 CAD. Its return on equity is -24.99%, and its return on assets is -10.00%, both of which are significantly below the industry median for pharmaceutical companies. These metrics indicate that the company is not generating returns for its shareholders or effectively utilizing its assets.
Auxly Cannabis Group Inc's revenue is concentrated in a single business segment, as disclosed in its financial statements. The company does not provide detailed geographic revenue breakdowns, but its operations are primarily based in Canada. This concentration increases the company's exposure to local market conditions and regulatory changes.
The company's growth trajectory is uncertain, with no clear indication of revenue growth in the current fiscal year. The lack of positive revenue growth, combined with ongoing losses, suggests that the company is struggling to achieve profitability. Analysts have assigned a mean price target of 0.25 CAD, with a mean recommendation of 2.00, indicating a neutral stance.
The company faces several risk factors, including liquidity constraints and the potential for dilution. The risk assessment indicates a medium liquidity risk, with the company's net cash position being negative after accounting for total debt. The dilution risk is currently low, but the company's ongoing losses and capital expenditures may necessitate future equity raises, which could dilute existing shareholders.
Recent events, including the company's financial performance and analyst estimates, suggest that the company is under pressure to improve its financial position. The company has not disclosed any major new product launches or strategic initiatives that could drive future growth. The lack of positive developments may continue to impact investor sentiment and the company's stock price.
- Auxly Cannabis Group Inc is operating at a net loss with a return on equity of -24.99% and a return on assets of -10.00%.
- The company's liquidity position is weak, with a current ratio of 0.71 and a debt-to-equity ratio of 0.79.
- Revenue is concentrated in a single business segment, increasing exposure to local market conditions.
- Analysts have assigned a neutral stance with a mean price target of 0.25 CAD.
- The company faces liquidity and dilution risks, with ongoing losses and capital expenditures.
Bull / Bear case
Generated · model-assistedAuxly generated CAD 122.3 million in revenue during FY-1, representing a 21% year-over-year increase from the prior period.
The company achieved positive operating income of CAD 1.1 million in FY-1, marking a significant turnaround from previous losses.
Analyst consensus suggests a 56.2% upside potential, with a mean price target of CAD 0.25 versus the current market price.
Long-term debt decreased significantly to CAD 68.5 million in FY-1, down from CAD 159.0 million in the prior period.
Gross profit expanded to CAD 53.5 million in FY-1, indicating improved core profitability before operating expenses.
The company faces high credit risk and medium liquidity risk, posing significant financial stability concerns for investors.
Free cash flow remained negative at CAD 8.8 million in FY-1, highlighting ongoing cash burn despite revenue growth.
In focus — financials by report
Revenue C$40.1M, +15,8% YoY; Operating income −80,9% YoY.
- ▍Revenue C$40.1M, +15,8% YoY
- ▍Operating income −80,9% YoY
- ▍Net income −78,7% YoY
- ▍Free cash flow −43,0% YoY
- ▍Net margin 2.4%
Revenue C$151.5M, +23,8% YoY; Operating income +2 911,2% YoY.
- ▍Revenue C$151.5M, +23,8% YoY
- ▍Operating income +2 911,2% YoY
- ▍Net income +356,0% YoY
- ▍Free cash flow +674,8% YoY
- ▍Net margin 27.6%
Revenue C$94.5M, +12,7% YoY; Operating income −201,7% YoY.
- ▍Revenue C$94.5M, +12,7% YoY
- ▍Operating income −201,7% YoY
- ▍Net income −286,2% YoY
- ▍Free cash flow −271,2% YoY
- ▍Net margin -137.9%
Revenue C$83.8M; Operating income -C$46.4M.
- ▍Revenue C$83.8M
- ▍Operating income -C$46.4M
- ▍Net margin -40.2%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,01 |
| Revenue | —no estimate | —no estimate | 162,6M CAD |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Auxly Cannabis Group Inc Market data — financials · 2026-05-30
- Auxly Cannabis Group Inc Market data — analyst estimates · 2026-05-30
Ownership & reference
Top holders
- Institutional Investor · as of 2026-03-310,07 %$308M
- Institutional Investor · as of 2026-03-310,00 %$12M